Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 12 (April 20), 2007: pp. 1539-1544
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.09.6305
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giantonio, B. J.
Right arrow Articles by Benson, A. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giantonio, B. J.
Right arrow Articles by Benson, A. B., III
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol, Peter J. O'Dwyer, Edith P. Mitchell, Steven R. Alberts, Michael A. Schwartz, Al B. Benson, III

From the University of Pennsylvania; Fox Chase Cancer Center; Thomas Jefferson University, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; Mount Sinai Medical Center, Miami, FL; and Northwestern University, Chicago, IL

Address reprint requests to Bruce J. Giantonio, MD, 12 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104; e-mail: Giantonio.bruce{at}jimmy.harvard.edu

Purpose Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer. This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer.

Patients and Methods Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone. The primary end point was overall survival, with additional determinations of progression-free survival, response, and toxicity.

Results The median duration of survival for the group treated with FOLFOX4 and bevacizumab was 12.9 months compared with 10.8 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for death = 0.75; P = .0011), and 10.2 months for those treated with bevacizumab alone. The median progression-free survival for the group treated with FOLFOX4 in combination with bevacizumab was 7.3 months, compared with 4.7 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for progression = 0.61; P < .0001), and 2.7 months for those treated with bevacizumab alone. The corresponding overall response rates were 22.7%, 8.6%, and 3.3%, respectively (P < .0001 for FOLFOX4 with bevacizumab v FOLFOX4 comparison). Bevacizumab was associated with hypertension, bleeding, and vomiting.

Conclusion The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal cancer.

Supported in part by Public Health Service Grants No. CA23318, CA66636, CA21115, CA15488, CA27525, CA17145; the National Cancer Institute, National Institutes of Health; and the Department of Health and Human Services.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
E. D. Saad, A. Katz, P. M. Hoff, and M. Buyse
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
Ann. Onc., November 9, 2009; (2009) mdp523v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Van Cutsem, F. Rivera, S. Berry, A. Kretzschmar, M. Michael, M. DiBartolomeo, M.-A. Mazier, J.-L. Canon, V. Georgoulias, M. Peeters, et al.
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
Ann. Onc., November 1, 2009; 20(11): 1842 - 1847.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
J. Clin. Oncol., October 10, 2009; 27(29): 4865 - 4873.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Grothey and D. J. Sargent
Reply to F. Montagnani et al
J. Clin. Oncol., October 1, 2009; 27(28): e134 - e135.
[Full Text] [PDF]

Home page
 The OncologistHome page
N. Damjanov, J. Weiss, and D. G. Haller
Resection of the Primary Colorectal Cancer Is Not Necessary in Nonobstructed Patients with Metastatic Disease
Oncologist, October 1, 2009; 14(10): 963 - 969.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Medical OncologyHome page
A. Grothey
Review: Medical treatment of advanced colorectal cancer in 2009
Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 55 - 68.
[Abstract] [PDF]

Home page
 Jpn J Clin OncolHome page
J. Iwasaki and S.-i. Nihira
Anti-angiogenic Therapy Against Gastrointestinal Tract Cancers
Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 543 - 551.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Kozloff, M. U. Yood, J. Berlin, P. J. Flynn, F. F. Kabbinavar, D. M. Purdie, M. A. Ashby, W. Dong, M. M. Sugrue, A. Grothey, et al.
Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study
Oncologist, September 1, 2009; 14(9): 862 - 870.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. A. Poultsides, E. L. Servais, L. B. Saltz, S. Patil, N. E. Kemeny, J. G. Guillem, M. Weiser, L. K.F. Temple, W. D. Wong, and P. B. Paty
Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment
J. Clin. Oncol., July 10, 2009; 27(20): 3379 - 3384.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. J. Cohen, C. J. A. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath, N. Y. Gabrail, J. Picus, M. A. Morse, E. Mitchell, M. C. Miller, et al.
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
Ann. Onc., July 1, 2009; 20(7): 1223 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Banerjee and M. Gore
The Future of Targeted Therapies in Ovarian Cancer
Oncologist, July 1, 2009; 14(7): 706 - 716.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. R. Fleming, M. D. Rothmann, and H. L. Lu
Issues in Using Progression-Free Survival When Evaluating Oncology Products
J. Clin. Oncol., June 10, 2009; 27(17): 2874 - 2880.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. S. Shord, L. R. Bressler, L. A. Tierney, S. Cuellar, and A. George
Understanding and managing the possible adverse effects associated with bevacizumab
Am. J. Health Syst. Pharm., June 1, 2009; 66(11): 999 - 1013.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Overman, G. R. Varadhachary, S. Kopetz, R. Adinin, E. Lin, J. S. Morris, C. Eng, J. L. Abbruzzese, and R. A. Wolff
Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater
J. Clin. Oncol., June 1, 2009; 27(16): 2598 - 2603.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Van Cutsem, W. L. Vervenne, J. Bennouna, Y. Humblet, S. Gill, J.-L. Van Laethem, C. Verslype, W. Scheithauer, A. Shang, J. Cosaert, et al.
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
J. Clin. Oncol., May 1, 2009; 27(13): 2231 - 2237.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, and J. P. Spano
Management of hypertension in angiogenesis inhibitor-treated patients
Ann. Onc., May 1, 2009; 20(5): 807 - 815.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. G. Fakih, L. Pendyala, G. Fetterly, K. Toth, J. A. Zwiebel, I. Espinoza-Delgado, A. Litwin, Y. M. Rustum, M. E. Ross, J. L. Holleran, et al.
A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer
Clin. Cancer Res., May 1, 2009; 15(9): 3189 - 3195.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Shojaei, X. Wu, X. Qu, M. Kowanetz, L. Yu, M. Tan, Y. G. Meng, and N. Ferrara
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
PNAS, April 21, 2009; 106(16): 6742 - 6747.
[Abstract] [Full Text] [PDF]

Home page
 AM J HOSP PALLIAT CAREHome page
R. L. Barros Costa
Review Article: Targeted Therapy: Comprehensive Review
American Journal of Hospice and Palliative Medicine, April 1, 2009; 26(2): 137 - 146.
[Abstract] [PDF]

Home page
 JCOHome page
E. L. Korn, B. Freidlin, and M. Mooney
Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005
J. Clin. Oncol., April 1, 2009; 27(10): 1712 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, et al.
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
J. Clin. Oncol., March 10, 2009; 27(8): 1227 - 1234.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. M Gressett and S. R Shah
Intricacies of Bevacizumab-Induced Toxicities and Their Management
Ann. Pharmacother., March 1, 2009; 43(3): 490 - 501.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Hecht, E. Mitchell, T. Chidiac, C. Scroggin, C. Hagenstad, D. Spigel, J. Marshall, A. Cohn, D. McCollum, P. Stella, et al.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Clin. Oncol., February 10, 2009; 27(5): 672 - 680.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. D. Blanke
Dual-Antibody Therapy in Advanced Colorectal Cancer: Gather Ye Rosebuds While Ye May
J. Clin. Oncol., February 10, 2009; 27(5): 655 - 658.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Kolinsky, B.-Q. Shen, Y.-E Zhang, J. Kohles, U. Dugan, T. F. Zioncheck, D. Heimbrook, K. Packman, and B. Higgins
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models
Mol. Cancer Ther., January 1, 2009; 8(1): 75 - 82.
[Abstract] [Full Text] [PDF]

Home page
 VASC ENDOVASCULAR SURGHome page
D. M. Birk, J. Barbato, L. Mureebe, and R. A. Chaer
Basic Science Review: Current Insights on the Biology and Clinical Aspects of VEGF Regulation
Vascular and Endovascular Surgery, January 1, 2009; 42(6): 517 - 530.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Ma and D. J. Waxman
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Mol. Cancer Ther., December 1, 2008; 7(12): 3670 - 3684.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Grothey, M. M. Sugrue, D. M. Purdie, W. Dong, D. Sargent, E. Hedrick, and M. Kozloff
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
J. Clin. Oncol., November 20, 2008; 26(33): 5326 - 5334.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. M. Ellis and D. G. Haller
Bevacizumab Beyond Progression: Does This Make Sense?
J. Clin. Oncol., November 20, 2008; 26(33): 5313 - 5315.
[Full Text] [PDF]

Home page
 JAMAHome page
S. R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-analysis
JAMA, November 19, 2008; 300(19): 2277 - 2285.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. B. Kesmodel, L. M. Ellis, E. Lin, G. J. Chang, E. K. Abdalla, S. Kopetz, J.-N. Vauthey, M. A. Rodriguez-Bigas, S. A. Curley, and B. W. Feig
Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases
J. Clin. Oncol., November 10, 2008; 26(32): 5254 - 5260.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. M. Ellis and D. J. Hicklin
Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy
Clin. Cancer Res., October 15, 2008; 14(20): 6371 - 6375.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Booth
Bevacizumab in Advanced Colorectal Cancer: A Challenge to the Current Paradigm
J. Clin. Oncol., October 1, 2008; 26(28): 4693 - 4694.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
D. Pereg and M. Lishner
Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?
Eur. Heart J., October 1, 2008; 29(19): 2325 - 2326.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. H. O'Neil and R. M. Goldberg
Innovations in Chemotherapy for Metastatic Colorectal Cancer: An Update of Recent Clinical Trials
Oncologist, October 1, 2008; 13(10): 1074 - 1083.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Cannistra
Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies
J. Clin. Oncol., August 1, 2008; 26(22): 3665 - 3667.
[Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
C. P. Carden, J. M.G. Larkin, and M. A. Rosenthal
What is the risk of intracranial bleeding during anti-VEGF therapy?
Neuro-oncol, August 1, 2008; 10(4): 624 - 630.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. S. Hochster, L. L. Hart, R. K. Ramanathan, B. H. Childs, J. D. Hainsworth, A. L. Cohn, L. Wong, L. Fehrenbacher, Y. Abubakr, M. W. Saif, et al.
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
J. Clin. Oncol., July 20, 2008; 26(21): 3523 - 3529.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Shitara, M. Munakata, O. Muto, and Y. Sakata
Metastatic Rectal Cancer Responding to Third-line Therapy Employing Bevacizumab After Failure of Oxaliplatin and Irinotecan: Case Report
Jpn. J. Clin. Oncol., July 1, 2008; 38(7): 493 - 496.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. R. Molhoek, H. Griesemann, J. Shu, J. E. Gershenwald, D. L. Brautigan, and C. L. Slingluff Jr.
Human Melanoma Cytolysis by Combined Inhibition of Mammalian Target of Rapamycin and Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2
Cancer Res., June 1, 2008; 68(11): 4392 - 4397.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. B. Saltz, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.-S. Yang, F. Rivera, et al.
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
J. Clin. Oncol., April 20, 2008; 26(12): 2013 - 2019.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
L. M Ellis
Resistance to Anti-VEGF Therapy
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 203 - 207.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. K. Oldham and R. O. Dillman
Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
J. Clin. Oncol., April 10, 2008; 26(11): 1774 - 1777.
[Full Text] [PDF]

Home page
 Ann OncolHome page
B. D. Badgwell, E. R. Camp, B. Feig, R. A. Wolff, C. Eng, L. M. Ellis, and J. N. Cormier
Management of bevacizumab-associated bowel perforation: a case series and review of the literature
Ann. Onc., March 1, 2008; 19(3): 577 - 582.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Folprecht, J. Tabernero, C.-H. Kohne, C. Zacharchuk, L. Paz-Ares, F. Rojo, S. Quinn, E. Casado, R. Salazar, R. Abbas, et al.
Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer
Clin. Cancer Res., January 1, 2008; 14(1): 215 - 223.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
S. M. Lichtman
Pharmacology of Antineoplastic Agents for Older Patients
ASCO Educational Book, January 1, 2008; 2008(1): 210 - 214.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
A. Saad, R. Beto, J. Abraham, and S. C. Remick
Cardiovascular Safety and Toxicity Profile of New Molecularly Targeted Anticancer Agents
ASCO Educational Book, January 1, 2008; 2008(1): 428 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N.C. Ton, G.J.M. Parker, A. Jackson, S. Mullamitha, G.A. Buonaccorsi, C. Roberts, Y. Watson, K. Davies, S. Cheung, L. Hope, et al.
Phase I Evaluation of CDP791, a PEGylated Di-Fab' Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2
Clin. Cancer Res., December 1, 2007; 13(23): 7113 - 7118.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Buechele
Comments on Final Report of the AIO Colorectal Cancer Group Study: Fluorouracil/Oxaliplatin Versus Capecitabine/Oxaliplatin
J. Clin. Oncol., November 1, 2007; 25(31): 5041 - 5042.
[Full Text] [PDF]

Home page
 JCOHome page
I. E. Haines
A Positive Step Forward, but More Needed to Maximize Cost Benefits of New-Generation Cancer Therapies
J. Clin. Oncol., September 1, 2007; 25(25): e31 - e32.
[Full Text] [PDF]

Home page
 The OncologistHome page
S. E. Strome, E. A. Sausville, and D. Mann
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Oncologist, September 1, 2007; 12(9): 1084 - 1095.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online